Dr. Michael Adam Joins Hope Biosciences To Oversee Pharmaceutical & Manufacturing Operations And Regulatory Affairs

Press Release (ePRNews.com) - IRVINE, Calif. - Feb 15, 2017 - HOPE BIOSCIENCES, INC. announced today that Dr. Michael Adam has joined the management team to oversee Pharmaceutical and Manufacturing Operations as well as Regulatory Affairs and Quality Assurance.

Dr. Adam has held senior leadership roles at Pfizer La Jolla, Spectrum Pharmaceuticals, A. P. Pharma, and most recently at Heron Therapeutics. He has extensive development and operations experience having managed regulatory affairs, quality, pharmaceutical sciences, manufacturing, and product development functions from candidate identification through to marketed product approval in several therapeutic areas. Dr. Adam will report to George Uy, CEO and President of Hope Biosciences.

“We are happy to have Dr. Adam bring his leadership and management experience to the developing HOPE BIOSCIENCES’ team”, stated Mr. Uy. “With Michael coming on board we will be accelerating the development of HOPE-888 (nuc-Gemcitabine) and HOPE-777 (MERTK/AXL kinase inhibitor).”

About HOPE BIOSCIENCES, INC.
HOPE is a privately-owned biopharmaceutical company based in Irvine, California focused on licensing and commercializing anti-cancer drugs that address high unmet medical needs. HOPE has two unique assets currently in IND-enabling studies, including nuc-gemcitabine (HOPE-888), and a highly potent MERTK/AXL/pan-cMET kinase inhibitor (HOPE-777).

Hope in the face of difficulty. Hope in the face of uncertainty. The audacity of Hope!” President Barack Obama.

CONTACTS:

HOPE BIOSCIENCES, INC.

gu@hopebiosci.com

Source : HOPE BIOSCIENCES, INC.
Business Info :
HOPE BIOSCIENCES, INC.

You may also like this  

CATEGORIES : Healthcare
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login